[Results of a multicentric clinical study of mezlocillin in Japan (author's transl)].
In a clinical trial including 701 patients 6-((R)-2-[3-methylsulfonyl-2-oxo-imidazolidine-1-carboxamido]-2-phenyl-acetamido)-penicillanic acid sodium salt (mezlocillin, Baypen) proved effective in the treatment of severe infections. It showed a particularly high efficacy in septicaemia and endocarditis and in purulent meningitis. In cases unresponsive to previous treatment with other antibiotics mezlocillin was effective in about two-thirds of the cases. Side effects were slight and of the same nature as those accompanying other penicillins.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007223:Infant; D007564:Japan; D008297:Male; D008802:Mezlocillin; D008875:Middle Aged; D010406:Penicillins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D010406:Penicillins; D008802:Mezlocillin
Ergebnisse multizentrischer klinischer Prüfungen mit Mezlocillin in Japan.